Marker Therapeutics, Inc. (MRKR) News
Filter MRKR News Items
MRKR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRKR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRKR News From Around the Web
Below are the latest news stories about MARKER THERAPEUTICS INC that investors may wish to consider to help them evaluate MRKR as an investment opportunity.
Marker Therapeutics Announces $16.1 Million Private PlacementStrategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cellsHOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has entered into a securities purchase agreement |
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with LymphomaAPOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS) HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based |
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic CancerHOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer |
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors SymposiumHOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. This virtual investor event will |
Marker Therapeutics Leads 3 Noteworthy US Penny StocksAs the U.S. stock market takes a breather from its recent rally, investors are keenly watching for insights from upcoming economic reports and policy shifts. Despite the fluctuating conditions, penny stocks remain an intriguing segment for investors seeking growth opportunities in smaller or newer companies. Though often considered a niche area, these stocks can offer significant potential when backed by strong financial health and clear growth prospects. |
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology SummitHOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024. |
Marker Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsMarker Therapeutics ( NASDAQ:MRKR ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.93m (up by US$1.67m... |
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesMarker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancerHOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and |
US Penny Stocks To Consider In October 2024Major U.S. stock indexes have seen a downturn recently, with the Dow Jones, S&P 500, and Nasdaq Composite all experiencing declines amid rising Treasury yields and mixed earnings reports. Despite these fluctuations, there remains potential in the market for those willing to explore beyond established giants. Penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at attractive price points when backed by strong fundamentals and solid... |
Marker Therapeutics price target raised to $19 from $11 at LadenburgLadenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing additional responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and tells investors in a research note that Marker’s management appears focused on gathering a comprehensive dataset with sufficient statistical and clinical significance, which would support adva |